These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26902493)

  • 1. Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction.
    Gueret A; Harouki N; Favre J; Galmiche G; Nicol L; Henry JP; Besnier M; Thuillez C; Richard V; Kolkhof P; Mulder P; Jaisser F; Ouvrard-Pascaud A
    Hypertension; 2016 Apr; 67(4):717-23. PubMed ID: 26902493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.
    Lavall D; Jacobs N; Mahfoud F; Kolkhof P; Böhm M; Laufs U
    Biochem Pharmacol; 2019 Oct; 168():173-183. PubMed ID: 31283930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction.
    Lax A; Sanchez-Mas J; Asensio-Lopez MC; Fernandez-Del Palacio MJ; Caballero L; Garrido IP; Pastor-Perez FJ; Januzzi JL; Pascual-Figal DA
    JACC Heart Fail; 2015 Jan; 3(1):50-58. PubMed ID: 25458175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice.
    Pieronne-Deperrois M; Guéret A; Djerada Z; Crochemore C; Harouki N; Henry JP; Dumesnil A; Larchevêque M; do Rego JC; do Rego JL; Nicol L; Richard V; Jaisser F; Kolkhof P; Mulder P; Monteil C; Ouvrard-Pascaud A
    ESC Heart Fail; 2021 Jun; 8(3):1933-1943. PubMed ID: 33742556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway.
    Martínez-Martínez E; Buonafine M; Boukhalfa I; Ibarrola J; Fernández-Celis A; Kolkhof P; Rossignol P; Girerd N; Mulder P; López-Andrés N; Ouvrard-Pascaud A; Jaisser F
    Hypertension; 2017 Dec; 70(6):1148-1156. PubMed ID: 29061727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.
    Bostick B; Habibi J; DeMarco VG; Jia G; Domeier TL; Lambert MD; Aroor AR; Nistala R; Bender SB; Garro M; Hayden MR; Ma L; Manrique C; Sowers JR
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1126-35. PubMed ID: 25747754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
    Lachaux M; Barrera-Chimal J; Nicol L; Rémy-Jouet I; Renet S; Dumesnil A; Wecker D; Richard V; Kolkhof P; Jaisser F; Ouvrard-Pascaud A; Mulder P
    Diabetes Obes Metab; 2018 Oct; 20(10):2399-2407. PubMed ID: 29862614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.
    Dutzmann J; Musmann RJ; Haertlé M; Daniel JM; Sonnenschein K; Schäfer A; Kolkhof P; Bauersachs J; Sedding DG
    PLoS One; 2017; 12(9):e0184888. PubMed ID: 28926607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
    Poulsen SH
    Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of smooth muscle cell mineralocorticoid receptor in vascular tone.
    Tarjus A; Belozertseva E; Louis H; El Moghrabi S; Labat C; Lacolley P; Jaisser F; Galmiche G
    Pflugers Arch; 2015 Aug; 467(8):1643-50. PubMed ID: 25262754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats.
    Tu L; Thuillet R; Perrot J; Ottaviani M; Ponsardin E; Kolkhof P; Humbert M; Viengchareun S; Lombès M; Guignabert C
    Hypertension; 2022 Oct; 79(10):2262-2273. PubMed ID: 35979822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness.
    Galmiche G; Pizard A; Gueret A; El Moghrabi S; Ouvrard-Pascaud A; Berger S; Challande P; Jaffe IZ; Labat C; Lacolley P; Jaisser F
    Hypertension; 2014 Mar; 63(3):520-526. PubMed ID: 24296280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity.
    Lother A; Bergemann S; Kowalski J; Huck M; Gilsbach R; Bode C; Hein L
    Cardiovasc Res; 2018 Feb; 114(2):282-290. PubMed ID: 28430882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
    Landmesser U; Engberding N; Bahlmann FH; Schaefer A; Wiencke A; Heineke A; Spiekermann S; Hilfiker-Kleiner D; Templin C; Kotlarz D; Mueller M; Fuchs M; Hornig B; Haller H; Drexler H
    Circulation; 2004 Oct; 110(14):1933-9. PubMed ID: 15466656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.